Supercharged immune cells take on melanoma in early trial
NCT ID NCT01955460
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 23 times
Summary
This early-phase study tests a new way to fight advanced melanoma. Doctors take a patient's own immune cells (T-cells), modify them in a lab to resist a tumor-blocking signal (TGF-beta), and return them to the body along with a drug (IL-2) that boosts their activity. The goal is to see if this approach is safe and possible to do. About 34 people with stage III or IV melanoma that has spread are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III CUTANEOUS MELANOMA AJCC V7 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.